Evidence map›Paper›PMID 38730548›Full record

ArticleJNCI cancer spectrum2024

Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume.

Enoch Chang, Franklin C L Wong, Beth A Chasen, William D Erwin, Prajnan Das, Emma B Holliday, Albert C Koong, Ethan B Ludmir, Bruce D Minsky, Sonal S Noticewala and 22 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02626312 (Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02626312 phase1terminatednot on this map

Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2016 to 2026Enrolled36ConditionsCholangiocarcinoma, Cirrhosis, Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the LiverArmsLaboratory Biomarker Analysis, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Radiation-Induced Liver Injury: An Overview.Journal of hepatocellular carcinoma · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Enoch ChangRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2879-5445
Franklin C L WongNuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Beth A ChasenNuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William D ErwinImaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Prajnan DasRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emma B HollidayRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Albert C KoongRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ethan B LudmirRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5472-5344
Bruce D MinskyRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sonal S NoticewalaRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Grace L SmithRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cullen M TaniguchiRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria J RodriguezRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sam BeddarRadiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rachael M Martin-PaulpeterRadiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joshua S NiedzielskiRadiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gabriel O SawakuchiRadiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emil SchuelerRadiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luis A PerlesRadiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lianchun XiaoBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Janio SzklarukDiagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peter C ParkRadiology Physics, University of California, Davis, Davis, CA, USA.
Arvind N DasariMedical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahmed O KasebMedical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bryan K KeeMedical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sunyoung S LeeMedical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael J OvermanMedical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason A WillisMedical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert A WolffMedical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ching-Wei D TzengSurgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6035-7288
Jean-Nicolas VautheySurgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4921-5427
Eugene J KoayRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7675-3461

Funding

Project 3: Enhanced Sensitivity of Tumors to Proton Beam Therapy: Mechanisms and Biomarkers.P01CA261669 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HONG, THEODORE S · 2021 to 2025
$14.0M
Optimization and Evaluation of Anatomical Models of Liver Radiation ResponseR01CA221971 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BROCK, KRISTY · 2018 to 2022
$1.8M
GE HealthcareNCI NIH HHS P01 CA261669NCI NIH HHS R01 CA221971Philips Healthcarethe National Institutes of Health R01CA221971
6 · The paper itself

Abstract

backgroundTraditional constraints specify that 700 cc of liver should be spared a hepatotoxic dose when delivering liver-directed radiotherapy to reduce the risk of inducing liver failure. We investigated the role of single-photon emission computed tomography (SPECT) to identify and preferentially avoid functional liver during liver-directed radiation treatment planning in patients with preserved liver function but limited functional liver volume after receiving prior hepatotoxic chemotherapy or surgical resection.

methodsThis phase I trial with a 3 + 3 design evaluated the safety of liver-directed radiotherapy using escalating functional liver radiation dose constraints in patients with liver metastases. Dose-limiting toxicities were assessed 6-8 weeks and 6 months after completing radiotherapy.

resultsAll 12 patients had colorectal liver metastases and received prior hepatotoxic chemotherapy; 8 patients underwent prior liver resection. Median computed tomography anatomical nontumor liver volume was 1584 cc (range = 764-2699 cc). Median SPECT functional liver volume was 1117 cc (range = 570-1928 cc). Median nontarget computed tomography and SPECT liver volumes below the volumetric dose constraint were 997 cc (range = 544-1576 cc) and 684 cc (range = 429-1244 cc), respectively. The prescription dose was 67.5-75 Gy in 15 fractions or 75-100 Gy in 25 fractions. No dose-limiting toxicities were observed during follow-up. One-year in-field control was 57%. One-year overall survival was 73%.

conclusionLiver-directed radiotherapy can be safely delivered to high doses when incorporating functional SPECT into the radiation treatment planning process, which may enable sparing of lower volumes of liver than traditionally accepted in patients with preserved liver function.

trial registrationNCT02626312.

Indexed as

Colorectal NeoplasmsLiverLiver NeoplasmsRadiotherapy, Image-GuidedTomography, Emission-Computed, Single-PhotonAdultAgedFemaleHumansMaleMiddle AgedOrgan SizeRadiotherapy DosageRadiotherapy Planning, Computer-AssistedTomography, X-Ray Computed

Identifiers

PMID38730548
PMCPMC11164414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.